1061 Stock Overview
An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Essex Bio-Technology Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.41 |
| 52 Week High | HK$5.15 |
| 52 Week Low | HK$2.15 |
| Beta | -0.11 |
| 1 Month Change | -3.92% |
| 3 Month Change | 67.68% |
| 1 Year Change | 75.70% |
| 3 Year Change | 16.05% |
| 5 Year Change | -13.36% |
| Change since IPO | 345.45% |
Recent News & Updates
A Look At The Fair Value Of Essex Bio-Technology Limited (HKG:1061)
Apr 29
Essex Bio-Technology Limited (HKG:1061) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Mar 28Recent updates
A Look At The Fair Value Of Essex Bio-Technology Limited (HKG:1061)
Apr 29Essex Bio-Technology Limited (HKG:1061) Stock Catapults 26% Though Its Price And Business Still Lag The Market
Mar 28Essex Bio-Technology Limited (HKG:1061) Surges 29% Yet Its Low P/E Is No Reason For Excitement
Oct 09Essex Bio-Technology's (HKG:1061) Upcoming Dividend Will Be Larger Than Last Year's
Aug 29Essex Bio-Technology Limited's (HKG:1061) Low P/E No Reason For Excitement
May 06Calculating The Fair Value Of Essex Bio-Technology Limited (HKG:1061)
Mar 21Essex Bio-Technology (HKG:1061) Has A Pretty Healthy Balance Sheet
Dec 07Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 07Essex Bio-Technology (HKG:1061) Is Due To Pay A Dividend Of HK$0.04
Aug 25Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?
Jun 22Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055
May 02Essex Bio-Technology (HKG:1061) Will Pay A Larger Dividend Than Last Year At HK$0.055
Mar 30Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Jun 29Is Essex Bio-Technology (HKG:1061) A Risky Investment?
Mar 31If You Had Bought Essex Bio-Technology (HKG:1061) Stock Five Years Ago, You Could Pocket A 40% Gain Today
Mar 13How Many Essex Bio-Technology Limited (HKG:1061) Shares Did Insiders Buy, In The Last Year?
Feb 15
Do Institutions Own Essex Bio-Technology Limited (HKG:1061) Shares?
Jan 25Essex Bio-Technology Limited's (HKG:1061) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Jan 04Essex Bio-Technology (HKG:1061) Seems To Use Debt Quite Sensibly
Dec 13Why Essex Bio-Technology's (HKG:1061) CEO Pay Matters
Nov 23Shareholder Returns
| 1061 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 1.4% | -6.4% | 2.1% |
| 1Y | 75.7% | 38.8% | 12.6% |
Return vs Industry: 1061 exceeded the Hong Kong Biotechs industry which returned 38.8% over the past year.
Return vs Market: 1061 exceeded the Hong Kong Market which returned 12.6% over the past year.
Price Volatility
| 1061 volatility | |
|---|---|
| 1061 Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 13.7% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 1061's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1061's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 1,450 | Haizhou Fang | www.essexbio.com |
Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally. The company operates through Ophthalmology, Surgical, and Provision of services segments. It researches and develops therapeutic fibroblast growth factor products to treat cellular proliferation, differentiation, and migration.
Essex Bio-Technology Limited Fundamentals Summary
| 1061 fundamental statistics | |
|---|---|
| Market cap | HK$2.49b |
| Earnings (TTM) | HK$307.22m |
| Revenue (TTM) | HK$1.67b |
8.1x
P/E Ratio1.5x
P/S RatioIs 1061 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1061 income statement (TTM) | |
|---|---|
| Revenue | HK$1.67b |
| Cost of Revenue | HK$171.15m |
| Gross Profit | HK$1.50b |
| Other Expenses | HK$1.19b |
| Earnings | HK$307.22m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.54 |
| Gross Margin | 89.75% |
| Net Profit Margin | 18.40% |
| Debt/Equity Ratio | 7.8% |
How did 1061 perform over the long term?
See historical performance and comparisonDividends
2.7%
Current Dividend Yield22%
Payout RatioDoes 1061 pay a reliable dividends?
See 1061 dividend history and benchmarks| Essex Bio-Technology dividend dates | |
|---|---|
| Ex Dividend Date | May 23 2025 |
| Dividend Pay Date | Jun 09 2025 |
| Days until Ex dividend | 8 days |
| Days until Dividend pay date | 25 days |
Does 1061 pay a reliable dividends?
See 1061 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 09:46 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Essex Bio-Technology Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| null null | Guoyuan Securities (HK) Ltd |
| Stella Xing | Nomura Securities Co. Ltd. |